IXHL

Incannex is a clinical-stage biopharma with no approved products and no material revenue: FY2025 sales of $86K came from rehab-clinic patient services, and management explicitly states it does 'not expect to generate material revenues unless and until our drug candidates are approved.' The entire equity story rests on three early programs — IHL-42X (OSA), PSX-001 (psilocybin for GAD), and IHL-675A (rheumatoid arthritis) — each pre-approval, each binary. Against that, the market is assigning a ~$1.38B market cap, a P/S of roughly 16,051x and ~100x the $13.4M of stockholders' equity. Nothing in the filing's numbers supports that valuation; it is pure speculative optionality.

The balance sheet cannot underwrite the story. Cash is $15.0M against operating cash burn of $12.5M — barely a year of runway — and the company concedes it 'will need substantial additional funding.' It has already answered that with dilution: shares outstanding exploded 1,870% year-over-year, and in July 2025 it filed to add up to $100M of ATM capacity on top of an existing program. For a company whose entire equity base is $13.4M, a $100M ATM overhang is the dominant fact — existing holders face relentless, near-certain dilution at whatever price the market allows.